carbamates has been researched along with Optic Nerve Diseases in 1 studies
Optic Nerve Diseases: Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Slusar, JE | 1 |
| Cairns, EA | 1 |
| Szczesniak, AM | 1 |
| Bradshaw, HB | 1 |
| Di Polo, A | 1 |
| Kelly, ME | 1 |
1 other study available for carbamates and Optic Nerve Diseases
| Article | Year |
|---|---|
The fatty acid amide hydrolase inhibitor, URB597, promotes retinal ganglion cell neuroprotection in a rat model of optic nerve axotomy.
Topics: Age Factors; Amidohydrolases; Animals; Axotomy; Benzamides; Carbamates; Cell Count; Disease Models, | 2013 |